最新ニュース Mativ Holdings (NYSE:MATV) 株価情報

Mativ Holdings

Mativ Holdings Inc is a diversified producer of premium specialty papers and resin-based products. It manufactures and sells paper and reconstituted tobacco products to the tobacco industry as well as specialized paper products. The company operates in two segments namely Advanced Materials and Structures, which manufactures resin-based products used in specialty applications in the filtration, infrastructure and construction, transportation, industrial, and medical end-markets, and Engineered Papers, which produces cigarette papers and reconstituted tobacco products for cigarette and cigar manufacturers, as well as various other non-tobacco paper products.

Mativ Holdings Inc

A consortium including&nbsp;General Motors&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>),&nbsp;Ford&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), and&nbsp;Stellantis&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) has voiced criticism over President Donald Trump&#8216;s latest trade agreement with the United Kingdom. The group fears the deal could harm the U.S. auto industry.
What Happened: The American Automotive Policy Council, representing the Detroit Three, expressed its apprehensions, stating, &#8220;Under&nbsp;this deal, it will now&nbsp;be cheaper to import a&nbsp;U.K. vehicle with very little&nbsp;U.S. content than a USMCA&nbsp;compliant vehicle from Mexico or&nbsp;Canada that is half American&nbsp;parts. This&nbsp;hurts American automakers, suppliers, and&nbsp;auto workers.&#8221;
The new trade agreement permits British automakers to export up to 100,000 cars to the U.S. annually at a reduced tariff rate of 10%. This figure is almost equivalent to Britain&#8217;s total exports last year and is considerably lower than the 25% tariff imposed on Mexico, Canada, and most other nations, reported Reuters.
The council is concerned that this deal could set a precedent, potentially disadvantaging vehicles assembled in Canada or Mexico in future agreements. The council also expressed hope that &#8220;this&nbsp;preferential access for U.K. vehicles&nbsp;over North American ones does&nbsp;not set a precedent for&nbsp;future negotiations with Asian and&nbsp;European competitors.&#8221;
SEE ALSO:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45298628/bitcoin-ethereum-xrp-dogecoin-explode-for-double-digit-percentage-gains-after-trump-trade-deal-news" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, XRP, Dogecoin Explode For Double-Digit Percentage Gains After Trump Trade Deal News &#8211; Benzinga</a>
Why It Matters:&nbsp;The U.S.-U.K. trade deal was&nbsp;<a href="https://www.benzinga.com/politics/25/05/45293839/trump-starmer-strike-us-uk-trade-deal-steel-cars-beef">sealed on Wednesday</a>, aiming to cut tariffs, strengthen industrial ties, and secure billions in new market access. 
However, the auto industry has been grappling with tariff uncertainties. Trump eased auto tariff impacts on parts and North American components under USMCA but kept the 25% tariff on imported vehicles, disappointing automakers hoping for broader relief.
&nbsp;<a href="https://www.benzinga.com/markets/25/05/45277938/ford-hikes-prices-of-select-mexico-produced-vehicles-amid-auto-tariff-uncertainty-report">Ford</a>&nbsp;recently hiked prices of select Mexico-produced vehicles, while&nbsp;<a href="https://www.benzinga.com/tech/25/05/45217767/ford-ceo-jim-farley-says-trumps-tariffs-could-cost-ford-1-5-billion-pulls-its-earnings-guidance">CEO Jim Farley warned</a>&nbsp;that Trump&#8217;s tariffs could cost the company $1.5 billion.&nbsp;The company also withdrew its annual earnings forecast, citing uncertainty caused by the Trump administration&#8217;s tariffs.
<a href="https://www.benzinga.com/news/earnings/25/05/45150325/gm-cut-its-2025-forecast-on-tariffs-but-core-business-holds-up-says-goldman-sachs">GM also cut its 2025 forecast</a>&nbsp;due to tariff uncertainties. The auto giant updated its forecast to reflect an expected tariff-related impact of $4 to $5 billion, given the current regulatory and policy landscape.
Ford stock climbed 8.2% over the past month, while General Motors rose 3.52% during the same period. On the other hand, Stellantis fell 2.37% over the past 30 days. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/25/05/45311187/the-picture-of-the-worlds-richest-man-killing-the-worlds-poorest-children-is-not-a-pretty-one-says-bill-gates-sla" target="_blank" rel="noreferrer noopener">Bill Gates Slams Elon Musk Over Abrupt USAID Cuts: &#8216;The Picture Of The World&#8217;s Richest Man Killing The World&#8217;s Poorest&#8230;&#8217;</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Tech

General

STLA

Ford, GM, Stellantis Slam Trump's UK Trade Deal: 'This Hurts American Automakers, Suppliers And Auto Workers'

NGVC

Natural Grocers Partners With Contented Hen To Offer Premium Eggs At Introductory Prices

Needham analyst John Todaro reiterates Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Buy and maintains $21 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Hut 8, Maintains $21 Price Target

Enbridge Sees 2023 To 2026 Near-term Growth Of 7%-9% For Adjusted EBITDA , 4%-6% For Adjusted EPS And Approximately 3% For DCF Per Share

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgrades Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades Vor Biopharma to Neutral

Macro Economic Events

Economics

Federal Reserve

Fed's Barr Said Tariffs May Put Fed in a Difficult Position Confronting Rising Inflation, Unemployment; Tariffs Could Lead to Disruption to the Global Supply Chain

Enbridge Says Doesn't Expect Tariffs To Have A Material Impact On Current Operations Or Deployment Of Capital

Fed's Barr Said Disruptions to Supply Networks Can Have Long and Lasting Impact on Prices and Output; Tariffs Could Create Persistent Upward Pressure on Inflation

Billionaire investor Bill Ackman opened up about the most painful chapter of his career—the collapse of his $4 billion investment in Valeant Pharmaceuticals. In a candid interview, he explained how the disaster nearly wrecked his firm, his finances, and his personal life.
What Happened: "We were not a passive investor, but we became a passive investor," Ackman said, calling Valeant "a very unusual investment for us." Unlike his typical hands-on approach, Pershing Square stood by as Valeant's acquisition-driven model fell apart. As the stock collapsed, investors began shorting Ackman&#8217;s other positions, compounding the damage. "I thought we could lose the business," he admitted on the Lex Fridman podcast last year.
At the same time, Ackman was dealing with a divorce, a lawsuit from a shareholder, and an attempt by Elliott Management to take control of his publicly traded investment vehicle. To fend off the takeover, he borrowed $300 million from JPMorgan and personally bought the shares needed to maintain control.
See Also: <a href="https://www.benzinga.com/news/global/25/05/45215257/bill-ackman-calls-tariffs-a-one-time-reset-warns-prolonged-china-fight-could-drag-market-slump-to-q2">Bill Ackman Calls Tariffs A &#8216;One Time Reset,&#8217; Warns Prolonged China Fight Could Drag Market Slump To Q2</a>
Why It Matters: The experience left him shaken but ultimately changed his approach. "There was a period of time where I didn't think I was going to make it," he said. In response, he etched Pershing Square's investment principles in stone and gave copies to every employee. 
Reflecting on the aftermath, Ackman said: "If you're making progress each day, you're in a good place. If you're not making progress each day, you're in a very bad place." The Valeant saga pushed him to refocus on process, discipline, and long-term thinking. From near collapse to recovery, Ackman's story is one of personal and professional resilience. "It was about love, it was about people believing in me, it was about sticking to it, it was about getting up every day," he said.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Bill Ackman&#039;s lowest point: $4 billion dollar loss &#x7C; Lex Fridman Podcast Clips" width="500" height="281" src="https://www.youtube.com/embed/TK60sFs2Cyo?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45219671/bill-ackmans-900m-boost-could-lift-howard-hughes-stock-above-key-technical-barrier-ahead-of-q1-earnings">Bill Ackman&#8217;s $900M Boost Could Lift Howard Hughes Stock Above Key Technical Barrier Ahead Of Q1 Earnings</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image Via Shutterstock

Success Stories

Bill Ackman Took A $4 Billion Hit But Says 'Making Progress Each Day' Was Key To Recovering From The Valeant Disaster

National Healthcare (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NHC#AMEX">NHC</a>) reported quarterly earnings of $1.59 per share. This is a 63.92 percent increase over earnings of $0.97 per share from the same period last year. The company reported $373.70 million in sales this quarter. This is a 25.75 percent increase over sales of $297.18 million the same period last year.

Earnings

National Healthcare Q1 Adj. EPS $1.59 Up From $0.97 YoY, Sales $373.70M Up From $297.18M YoY

Telsey Advisory Group analyst Dana Telsey maintains Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) with a Market Perform and lowers the price target from $3 to $1.25.

LESL

Telsey Advisory Group Maintains Market Perform on Leslies, Lowers Price Target to $1.25

Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.73) by 2.74 percent. This is a 94.21 percent increase over losses of $(12.27) per share from the same period last year.

Earnings Beats

BOLD

Boundless Bio Q1 EPS $(0.71) Beats $(0.73) Estimate

Telsey Advisory Group analyst Dana Telsey maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and maintains $92 price target.

Telsey Advisory Group Maintains Outperform on Tapestry, Maintains $92 Price Target

Ubiquiti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UI#NYSE">UI</a>) reported quarterly earnings of $3.00 per share which beat the analyst consensus estimate of $1.97 by 52.28 percent. This is a 134.38 percent increase over earnings of $1.28 per share from the same period last year. The company reported quarterly sales of $664.17 million which beat the analyst consensus estimate of $597.69 million by 11.12 percent. This is a 34.72 percent increase over sales of $493.00 million the same period last year.

Ubiquiti Q3 Adj. EPS $3.00 Beats $1.97 Estimate, Sales $664.17M Beat $597.69M Estimate

1stdibs.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DIBS#NASDAQ">DIBS</a>) sees Q2 sales of $21.200 million-$22.500 million vs $22.62 million analyst estimate.

Guidance

DIBS

1stdibs.com Sees Q2 Sales $21.200M-$22.500M vs $22.62M Est

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Prothena Corporation PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>)</h3>
<ul class="wp-block-list">
<li>On May 8, Prothena posted weaker-than-expected quarterly results. &#8220;We continue to meaningfully advance our wholly-owned and partnered programs across our protein dysregulation portfolio during this transformative year for Prothena. Most notably in 2025 we anticipate topline data in 2Q from the confirmatory Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis, conducted under a SPA agreement with the FDA with a primary endpoint of time to all-cause mortality at a statistical significance level of 0.10,&#8221; said Gene Kinney, Ph.D., President and Chief Executive Officer, Prothena. The company's stock fell around 31% over the past month and has a 52-week low of $7.01.</li>
<li>RSI Value: 21.9</li>
<li>PRTA Price Action: Shares of Prothena fell 2.6% to close at $7.10 on Thursday.</li>
<li>Edge Stock Ratings: 5.29 Momentum score with Value at 79.24. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/PRTA"><img loading="lazy" decoding="async" width="486" height="168" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png" alt="" class="wp-image-909704" style="width:347px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96.png 486w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09042900/image-96-300x104.png 300w" sizes="(max-width: 486px) 100vw, 486px" /></a></figure>
<h3 class="wp-block-heading">Rxsight Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 7, RxSight posted mixed quarterly results. &#8220;The exceptional clinical value delivered by our Light Adjustable Lens continues to drive significant enthusiasm among cataract surgeons,&#8221; said Ron Kurtz, Chief Executive Officer and President of RxSight. The company's stock fell around 15% over the past month and <a href="https://www.benzinga.com/quote/RXST">has a 52-week low</a> of $13.22.</li>
<li>RSI Value: 28.8</li>
<li>RXST Price Action: Shares of Rxsight dipped 11.2% to close at $13.23 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">RXST stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="917" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png" alt="" class="wp-image-909712" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-300x271.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043016/image-97-768x693.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Sarepta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>)</h3>
<ul class="wp-block-list">
<li>On May 6, Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst consensus estimate of losses of 95 cents. "In the first quarter, we achieved net product revenue of $611.5 million, a 70% increase over the same quarter prior year; our PMO franchise performed well at $236.5 million; and ELEVIDYS achieved $375 million, growing at 180% over the same quarter prior year. However, we also faced headwinds in the quarter. While we are taking a variety of actions to address and resolve these challenges, we have adjusted our guidance for 2025 to $2.3 billion to $2.6 billion," said Doug Ingram, CEO of Sarepta Therapeutics. The company's stock fell around 42% over the past five days and has a 52-week l<a href="https://www.benzinga.com/quote/SRPT">ow of $35.4</a>6.</li>
<li>RSI Value: 23.2</li>
<li>SRPT Price Action: Shares of Sarepta Therapeutics fell 0.5% to close at $36.52 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509">SRPT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0509"><img loading="lazy" decoding="async" width="876" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png" alt="" class="wp-image-909714" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98.png 876w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09043110/image-98-768x730.png 768w" sizes="(max-width: 876px) 100vw, 876px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a> 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

PRTA

RXST

SRPT

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

WIIM

WOLF

Wolfspeed shares are trading lower. The company reported mixed Q3 financial results

HUBS

HubSpot shares are trading lower after the company reported Q1 financial results. The company issued Q2 adjusted EPS guidance below estimates.

Needham analyst Mayank Tandon maintains Open Lending (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPRO#NASDAQ">LPRO</a>) with a Buy and raises the price target from $2 to $2.5.

LPRO

Needham Maintains Buy on Open Lending, Raises Price Target to $2.5

FLWS

1-800-FLOWERS.COM shares are trading lower after the company reported worse-than-expected Q3 financial results.

Press Releases

Mativ Announces Conference Call to Discuss Third Quarter 2024 Results

Mativ Announces Third Quarter 2024 Results

Mativ Releases 2023 ESG Report Highlighting Key Initiatives

CHASM Exclusively Licenses AgeNT® Express Transparent Conductive Film to Mativ for Heated Glass Solutions

Mativ Announces Conference Call to Discuss Fourth Quarter and Full Year 2024 Results

Mativ Announces Fourth Quarter and Full Year 2024 Results

Mutual Funds

DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

Mativ Appoints Shruti Singhal as President and CEO

Mativ Announces Conference Call to Discuss First Quarter 2025 Results

Mativ Announces First Quarter 2025 Results

AMBC

BBWI

CLSK

DASH

FLGT

FRPT

GDOT

GPRE

HAIN

HIMS

ISRG

KTOS

MATV

NEOG

PLTR

SATS

SPGI

AdvanSix

Braskem

Bolt Projects Holdings, Inc. - Common Stock

Bolt Projects Holdings

Cabot

Core Molding Technologies Inc Common Stock

Core Molding Technologies

CN Energy Group Inc. - Class A Ordinary Shares

CN Energy Group

Gulf Resources

Hawkins

Koppers Holdings

Kronos Worldwide

Loop Industries

Orion

Olin

Origin Materials, Inc. - Class A Common Stock

Origin Materials

PureCycle Technologies, Inc. - Common stock

PureCycle Technologies

Tronox Holdings

Trinseo

Westlake

Westlake Chemical Partners LP Common Units representing limited partner interests

Westlake Chemical

Stifel

Comments

Mativ Holdings

ニュース

最新ニュース Mativ Holdings (NYSE:MATV) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル